I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

ISPOR New Orleans, LA, USA, 18-22 May 2019

RETROSPECTIVE CLAIMS ANALYSIS OF TREATMENT DURATION, HEALTH CARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH FIRST-LINE TREATMENT OF NSCLC WITH AFATINIB VS. ERLOTINIB IN THE UNITED STATES

Samuelsen C, Lim J, Golembesky AK, Shrestha S, Wang L, Griebsch I

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

Duration of treatment among patients prescribed afatinib or erlotinib as first-line therapy for EGFR mutation-positive non-small-cell lung cancer in the USA

Jonathan Lim, Carl Samuelsen, Amanda Golembesky, Sulena Shrestha, Li Wang & Ingolf Griebsch

Related information

About afatinib

A detailed look at afatinib’s mechanism of action and the ErbB Family of receptors that are targeted by afatinib

Afatinib (GIOTRIF®) as monotherapy is approved for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic NSCLC with activating EGFR mutation(s); and locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy

FOR HEALTHCARE PROFESSIONALS ONLY